CytRx (CYTR +10.2%) says its completed the enrollment of 140 patients in its Phase 2b clinical...

|About: CytRx Corporation (CYTR)|By:, SA News Editor

CytRx (CYTR +10.2%) says its completed the enrollment of 140 patients in its Phase 2b clinical trial with its oral retinoid compound tamibarotene in combination with chemotherapeutic agents as a first-line treatment for patients with advanced non-small-cell lung cancer.